Recognized markers for neurodegeneration, specifically Alzheimer Disease, such as cerebrospinal fluid biomarkers (amyloid-β and tau proteins concentrations) and positron emission tomography imaging (FDG and amyloid) are not available in our cohort (35). The gene discussed is MAPT; the disease is Alzheimer disease.